What is Northland Capmk's Estimate for Indivior Q3 Earnings?

Indivior PLC (NASDAQ:INDV - Free Report) - Northland Capmk boosted their Q3 2025 EPS estimates for Indivior in a report released on Thursday, April 24th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.25 for the quarter, up from their prior forecast of $0.23. The consensus estimate for Indivior's current full-year earnings is $1.22 per share. Northland Capmk also issued estimates for Indivior's Q4 2025 earnings at $0.27 EPS and FY2026 earnings at $1.35 EPS.

A number of other research firms have also commented on INDV. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price for the company. Finally, Piper Sandler reduced their price target on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Stock Performance

INDV traded down $0.34 during trading on Friday, reaching $11.41. 396,546 shares of the company's stock were exchanged, compared to its average volume of 972,639. The company's fifty day moving average price is $9.55 and its 200-day moving average price is $10.38. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $18.59. The firm has a market capitalization of $1.57 billion, a PE ratio of -32.60 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million.

Hedge Funds Weigh In On Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in Indivior in the 4th quarter valued at $359,000. Stifel Financial Corp bought a new stake in Indivior in the 3rd quarter valued at $100,000. Hennion & Walsh Asset Management Inc. bought a new stake in Indivior in the 4th quarter valued at $1,192,000. Geode Capital Management LLC lifted its position in Indivior by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 132,239 shares of the company's stock valued at $1,289,000 after acquiring an additional 9,500 shares in the last quarter. Finally, VELA Investment Management LLC lifted its position in Indivior by 45.5% in the 4th quarter. VELA Investment Management LLC now owns 179,659 shares of the company's stock valued at $2,264,000 after acquiring an additional 56,224 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.